Cost-utility analyses of diagnostic laboratory tests: a systematic review
- PMID: 22152169
- DOI: 10.1016/j.jval.2011.05.044
Cost-utility analyses of diagnostic laboratory tests: a systematic review
Abstract
Objective: To review and evaluate the literature of cost-utility analyses (CUAs) regarding diagnostic laboratory testing.
Methods: We reviewed all articles related to diagnostic laboratory testing in the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), which contains detailed information on over 2000 published CUAs through 2008. We analyzed the extent to which the studies adhered to recommended practices for conducting and reporting cost-effectiveness analyses. We also recorded whether the studies contained information on diagnostic test accuracy and costs, and whether any account was taken of potential benefits or harms of testing that are unrelated to subsequent treatment, such as the reassurance value of testing.
Results: We identified 141 published CUAs pertaining to diagnostic laboratory testing published through 2008 which contained 433 separate incremental cost-effectiveness ratios. Prior to 2000, there were only 20 CUAs published, but the number averaged 13.4 annually thereafter. Most studies focused on hematology/oncology (n = 42, 30%) and obstetrics/gynecology (n = 36, 26%) applications. Approximately 63% (n = 89) of studies clearly reported information about the accuracy of the test, but only 10% (n = 14) mentioned test safety or possible risks. A small number (n = 10, 7%) mentioned or considered the potential value or harm of testing unrelated to treatment consequences. Over 55% of the reported incremental cost-effectiveness ratios (ICERs) were either dominant (more quality-adjusted life years for less cost), or below $50,000 per quality-adjusted life years gained (in 2008 US dollars).
Conclusion: The number of CUAs investigating laboratory diagnostic testing has increased substantially with applications to diverse clinical areas. The literature reveals many areas in which testing represents good value for money. The vast majority of studies have not considered preferences for test information unrelated to treatment consequences.
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
Similar articles
-
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. doi: 10.3310/hta10080. Health Technol Assess. 2006. PMID: 16545207
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation.Health Technol Assess. 2006 Jun;10(18):iii-iv, xi-259. doi: 10.3310/hta10180. Health Technol Assess. 2006. PMID: 16729917
-
Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.Health Technol Assess. 2012;16(17):1-266. doi: 10.3310/hta16170. Health Technol Assess. 2012. PMID: 22469073 Free PMC article.
-
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500. Health Technol Assess. 2012. PMID: 23302507 Free PMC article.
Cited by
-
Preventive Health Screening during the COVID-19 Pandemic: A Cross-Sectional Survey among 102,928 Internet Users in Poland.J Clin Med. 2022 Jun 14;11(12):3423. doi: 10.3390/jcm11123423. J Clin Med. 2022. PMID: 35743493 Free PMC article.
-
Improving American Healthcare Through "Clinical Lab 2.0": A Project Santa Fe Report.Acad Pathol. 2017 Apr 18;4:2374289517701067. doi: 10.1177/2374289517701067. eCollection 2017 Jan-Dec. Acad Pathol. 2017. PMID: 28725789 Free PMC article.
-
Use of Decision Modelling in Economic Evaluations of Diagnostic Tests: An Appraisal and Review of Health Technology Assessments in the UK.Pharmacoecon Open. 2019 Sep;3(3):281-291. doi: 10.1007/s41669-018-0109-9. Pharmacoecon Open. 2019. PMID: 30552651 Free PMC article. Review.
-
Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects.Front Med (Lausanne). 2021 Apr 16;8:642380. doi: 10.3389/fmed.2021.642380. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33937286 Free PMC article. Review.
-
Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and Meta-Analysis.Thyroid. 2022 Oct;32(10):1144-1157. doi: 10.1089/thy.2022.0269. Epub 2022 Sep 26. Thyroid. 2022. PMID: 35999710 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical